SCHEMBL714156

SCHEMBL714156

O=S(=O)(Nc1nccs1)c1ccc(Nc2cnn(Cc3ccc(Cl)cc3)c2)cn1

nearest known ligand 0.56

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 7/20 0.56
LMNA P02545 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
SCN3A Q9NY46 3/20 0.46
SCN5A Q14524 1/20 0.46
PPIA P62937 1/20 0.45
KDM4E B2RXH2 2/20 0.43
MAPT P10636 2/20 0.42
USP2 O75604 1/20 0.42
ESR2 Q92731 1/20 0.42
HSD17B10 Q99714 1/20 0.42
ALOX12 P18054 1/20 0.40
AVPR2 P30518 1/20 0.39
GPR27 Q9NS67 1/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
HTT P42858 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3677283 0.95 SCN9A (0.52) SCN9ALMNASMN1; SMN2SCN3ASCN5A
SCHEMBL710036 0.85 SCN9A (0.72) SCN9ALMNASMN1; SMN2SCN3ASCN5A
SCHEMBL713584 0.84 SCN9A (0.51) SCN9ALMNASMN1; SMN2SCN3ASCN5A
SCHEMBL711934 0.82 SCN9A (0.59) SCN9ALMNASMN1; SMN2SCN3ASCN5A
SCHEMBL710596 0.76 SCN9A (0.59) SCN9ASCN3ASCN5A
SCHEMBL711915 0.75 SCN9A (0.58) SCN9ASCN3ASCN5AMAPTUSP2
SCHEMBL16530895 0.72 SCN9A (1.00) SCN9A
SCHEMBL714026 0.70 SCN9A (0.53) SCN9ALMNASMN1; SMN2SCN3ASCN5A
SCHEMBL16531046 0.70 SCN9A (1.00) SCN9A
SCHEMBL709775 0.69 SCN9A (0.51) SCN9ASCN3ASCN5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8124610-B2 Sodium channel inhibitors ICAGEN INC. (US) 2012-02-28 US claimed
US-8124610-B2 Sodium channel inhibitors ICAGEN INC. (US) 2012-02-28 US disclosed
US-8124610-B2 Sodium channel inhibitors ICAGEN INC. (US) 2012-02-28 US disclosed
US-8124610-B2 Sodium channel inhibitors ICAGEN INC. (US) 2012-02-28 US disclosed
EP-2173743-A2 SODIUM CHANNEL INHIBITORS Icagen, Inc. (US) 2010-04-14 EP disclosed
US-20090023740-A1 SODIUM CHANNEL INHIBITORS ICAGEN (US) 2009-01-22 US disclosed
US-20090023740-A1 SODIUM CHANNEL INHIBITORS ICAGEN (US) 2009-01-22 US disclosed
US-20090023740-A1 SODIUM CHANNEL INHIBITORS ICAGEN (US) 2009-01-22 US disclosed
WO-2009012242-A2 SODIUM CHANNEL INHIBITORS ICAGEN, INC. (US) 2009-01-22 WO disclosed
WO-2009012242-A2 SODIUM CHANNEL INHIBITORS ICAGEN, INC. (US) 2009-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023740-A1 SODIUM CHANNEL INHIBITORS TRPV1, SCN1A, SCN2A SCN9A 17/4885LMNA 2921/4885SMN1; SMN2 287/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.